Hematopoietic Stem Cells Transplantation Market Analysis

Transplant Type (Allogeneic, Autologous)

The autologous segment is estimated to account for 58% share of the global hematopoietic stem cells transplantation market in the coming years owing to the rising prevalence of cancer. The incidence of cancer increases sharply with age, most likely because certain malignancies have accumulating risks that climb with age. The primary driver of the general increase in cancer risk is our advancing age, adoption of a Western lifestyle, poor eating practices, dairy products, processed foods, food additives, non-vegetarian diets, chemical pollution, constipation, and physical inactivity. This has significantly led to an increase in the demand for autologous hematopoietic stem cell transplantation as it is used to treat certain types of cancer.

An autologous stem cell transplant also known as autologous bone marrow transplant replaces malfunctioning bone marrow with healthy blood stem cells from within the body that are utilized for patients whose illnesses require heavy dosages of radiation and chemotherapy whereby the damaged bone marrow is partially restored with the use of an autologous stem cell transplant. According to estimates, there were more than 609,810 cancer deaths and over 1,957,310 new cancer cases in the US in 2023.

Application (Peripheral Blood Stem Cell Transplant, Bone Marrow Transplant, Cord Blood Transplant)

Hematopoietic stem cells transplantation market from the blood stem cell transplant segment is set to garner a notable share shortly. A blood stem cell transplant is a surgical technique that involves the transplantation of peripheral blood stem cells, cord blood, and bone marrow to introduce healthy blood-forming cells from a donor into the patient's circulation, where they start to proliferate and produce platelets, red blood cells, and white blood cells.

End-User (Hospitals, Specialty Centers)

The hospitals segment is anticipated to gain a robust market share of 54% during the forecast timeframe. The treatment for hematopoietic stem cell transplantation is usually done in hospitals as they offer a whole spectrum of transplant services and the availability of skilled medical professionals.

Our in-depth analysis of the global hematopoietic stem cells transplantation market includes the following segments:

Transplant Type	Allogeneic Autologous
Application	Peripheral Blood Stem Cell Transplant Bone Marrow Transplant Cord Blood Transplant
Disease Indication	Lymphoproliferative Disorders Leukemia Non-Malignant Disorders
End-User	Hospitals Specialty Centers

Frequently Asked Questions (FAQ)

Rising prevalence of leukemia and the growing advancements in stem cell transplantation technology are the major factors driving the growth of the market.

The market size of hematopoietic stem cells transplantation is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 â€“ 2036.

The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others.

The autologous segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.

Hematopoietic Stem Cells Transplantation Market Analysis